Health Care • Biotechnology: Pharmaceutical Preparations
$7.35 ▼ -0.17
(-2.26%)
MKT CAP: $496.7M • VOL: 794.4K
52W L $4 52W H $9
EOLS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $297.2M | $266.3M | $202.1M |
| YoY Revenue Growth % | +11.6% | +31.8% | — |
| Gross Profit | $197.1M | $182.3M | — |
| Gross Margin % | 66.3% | 68.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$32.7M | -$34.4M | -$49.2M |
| Operating Margin % | -11.0% | -12.9% | -24.4% |
| Net Income (GAAP) | -$51.6M | -$50.4M | -$61.7M |
| EBITDA (Normalized) | -$29.9M | -$33.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$42.3M | -$18.0M | -$34.0M |
| Capital Expenditures (CapEx) | $3.4M | $1.5M | — |
| Free Cash Flow (FCF) | -$45.7M | -$19.5M | -$34.0M |
| FCF Margin % | -15.4% | -7.3% | -16.8% |
| Return on Invested Capital (ROIC %) | -37.3% | -45.0% | — |
| Cash & Short-Term Equivalents | $53.8M | $87.0M | — |
| Total Debt (Short + Long Term) | $146.1M | $121.5M | — |
| Total Stockholders' Equity | -$23.1M | $5.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EOLS.